A person’s risk factors for melanoma could be used to tailor surveillance programs and skin self-examinations for those at particular risk, according to a recent study published in JAMA Dermatology. The study, “Clinical Features ... Read more

A new research study has found that malignant melanoma patients responded better to immunotherapy treatment when they had more diverse gut flora – microbes and bacteria that live in our ... Read more

Combining the investigational drugs encorafenib and binimetinib to treat advanced melanoma patients provides better progression-free survival and overall response rates than Zelboraf (vemurafenib) monotherapy, according to recent data. The information was presented ... Read more

Patients diagnosed in the late stages of melanoma who have BRAF mutations should be given immunotherapy as a first-line treatment, according to a systematic review published in JAMA Oncology. The study, “Systemic ... Read more